Strategic partnerships Exicure has a history of co-development agreements, including the Burixafor (GPC-100) collaboration with Adbiotech. This indicates a receptiveness to external partnerships and licensing deals, presenting opportunities to propose joint development or technology licensing for nucleic acid therapies in CNS disorders.

Clinical milestone leverage Recent news references clinical milestone settlements and stock-based payments related to collaborations. This suggests potential for milestone-driven collaborations or milestone-based licensing arrangements tied to progressing lead candidates or expanding into adjacent CNS indications.

Nasdaq and liquidity signals The company has faced Nasdaq integrity notices around minimum stockholders’ equity and delayed filings, signaling need for strategic financing, partner-backed funding, or co-development financing to de-risk programs and accelerate trials.

Neurological focus Exicure’s lead program targets SCN9A (Nav1.7) for non-opioid pain, with multiple CNS indications under exploration (Huntington’s, Angelman, Batten disease, spinocerebellar ataxia, sporadic ALS). This highlights a broad CNS opportunities pipeline ideal for partnership discussions with specialty pharma and biotech firms focusing on neurology and rare diseases.

In-house discovery platform The company operates rapid, automated high-throughput nucleic acid synthesis and screening in a dedicated facility. This capability can be a selling point for collaborators seeking scalable oligonucleotide chemistry, screening throughput, and internal validation to accelerate preclinical timelines.